Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Pinetree Therapeutics Inc. manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action, representing the active legal work being performed at the patent office. This single action suggests a targeted approach to securing intellectual property rights for a specific innovation.
The prosecution is overseen by 1 distinct examiner. This examiner is part of 1 distinct art unit, indicating that the company's current Biotechnology & Pharmaceuticals research is being evaluated within a specific technical framework. BUNNER, BRIDGET E is the busiest examiner for this portfolio. This individual is responsible for the 1 pending office action currently in the examination phase.
Because the busiest examiner pending count is 1, the company's immediate patenting outcomes are concentrated under one official. This allows for a direct and focused dialogue between the applicant and the 1 distinct examiner. However, it also means that the company's current success in the Biotechnology & Pharmaceuticals sector depends on the outcome of this single pending action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BUNNER, BRIDGET E | 1 | 64.5% | +19.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18040083 | NEUROPILIN AND ANGIOTENSIN CONVERTING ENZYME 2 FUSION PEPTIDES FOR TREATING VIRAL INFECTIONS | BUNNER, BRIDGET E | 31d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18040083 | NEUROPILIN AND ANGIOTENSIN CONVERTING ENZYME 2 FUSION PEPTIDES FOR TREATING VIRAL INFECTIONS | BUNNER, BRIDGET E | 31d overdue |
| Art Unit | Apps |
|---|---|
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18040083 | NEUROPILIN AND ANGIOTENSIN CONVERTING ENZYME 2 FUSION PEPTIDES FOR TREATING VIRAL INFECTIONS | BUNNER, BRIDGET E | 1647 | §102§112 | Final Rejection | 31d overdue | Pending | Jan 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial